CA2871714C - Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies - Google Patents

Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies Download PDF

Info

Publication number
CA2871714C
CA2871714C CA2871714A CA2871714A CA2871714C CA 2871714 C CA2871714 C CA 2871714C CA 2871714 A CA2871714 A CA 2871714A CA 2871714 A CA2871714 A CA 2871714A CA 2871714 C CA2871714 C CA 2871714C
Authority
CA
Canada
Prior art keywords
group
formula
compound
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2871714A
Other languages
English (en)
French (fr)
Other versions
CA2871714A1 (en
Inventor
Ludovic Clarion
Marcel Mersel
Didier Petite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BETA INNOV
Original Assignee
BETA INNOV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BETA INNOV filed Critical BETA INNOV
Publication of CA2871714A1 publication Critical patent/CA2871714A1/en
Application granted granted Critical
Publication of CA2871714C publication Critical patent/CA2871714C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2871714A 2012-05-10 2013-05-07 Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies Active CA2871714C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305518.8 2012-05-10
EP12305518.8A EP2662382B1 (fr) 2012-05-10 2012-05-10 Dérivés de stérol, leur procédé de préparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement du glioblastome multiple
US201261656151P 2012-06-06 2012-06-06
US61/656,151 2012-06-06
PCT/IB2013/053669 WO2013168096A1 (en) 2012-05-10 2013-05-07 Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies

Publications (2)

Publication Number Publication Date
CA2871714A1 CA2871714A1 (en) 2013-11-14
CA2871714C true CA2871714C (en) 2022-09-20

Family

ID=46149353

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871714A Active CA2871714C (en) 2012-05-10 2013-05-07 Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies

Country Status (23)

Country Link
US (1) US10800806B2 (,)
EP (2) EP2662382B1 (,)
JP (1) JP6270823B2 (,)
KR (1) KR102160316B1 (,)
CN (1) CN104302655B (,)
BR (1) BR112014026948B1 (,)
CA (1) CA2871714C (,)
CY (2) CY1117723T1 (,)
DK (2) DK2662382T3 (,)
ES (2) ES2580331T3 (,)
HR (2) HRP20180345T1 (,)
HU (2) HUE029243T2 (,)
IN (1) IN2014DN09437A (,)
LT (1) LT2847204T (,)
ME (1) ME02436B (,)
PL (2) PL2662382T3 (,)
PT (2) PT2662382T (,)
RS (2) RS54926B1 (,)
RU (1) RU2627710C2 (,)
SI (2) SI2662382T1 (,)
SM (2) SMT201800147T1 (,)
TR (1) TR201802700T4 (,)
WO (1) WO2013168096A1 (,)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3013048A1 (fr) * 2013-11-12 2015-05-15 Beta Innov Derive de sterol, son procede de preparation, composition pharmaceutique le contenant et son utilisation pour le traitement du glioblastome multiforme
EP3593789A1 (fr) * 2018-07-11 2020-01-15 Beta Innov Composition contenant un dérivé de 7beta-hydroxycholestérol et un véhicule lipidique, et son utilisation dans le traitement de pathologies néoplasiques
KR102689231B1 (ko) * 2021-05-18 2024-07-30 연세대학교 산학협력단 암의 예방, 개선 또는 치료용 조성물
WO2022245122A1 (ko) * 2021-05-18 2022-11-24 연세대학교 산학협력단 암의 예방, 개선 또는 치료용 조성물
US20260042871A1 (en) * 2022-08-04 2026-02-12 University Of Massachusetts Cholesterol-modified hyaluronic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602100D0 (sv) * 1996-05-30 1996-05-30 Magnus Axelson New pharmaceuticals
RU2005112247A (ru) * 2002-09-25 2006-01-20 Форбз Меди-Тек Инк. (Ca) Новые структуры и композиции, содержащие стеролы и/или станолы и определенные классы противовоспалительных средств, и их применение для лечения или предупреждения сердечно-сосудистого заболевания, лежащих в его основе состояний, включая гиперлипидемию, и других нарушений, при которых воспаление является частью их этиологии или проявления

Also Published As

Publication number Publication date
PT2847204T (pt) 2018-03-21
HUE029243T2 (en) 2017-02-28
JP2015520146A (ja) 2015-07-16
PL2662382T3 (pl) 2016-10-31
SMT201600215B (it) 2016-08-31
US20150086615A1 (en) 2015-03-26
TR201802700T4 (tr) 2018-03-21
CN104302655A (zh) 2015-01-21
ES2662123T3 (es) 2018-04-05
US10800806B2 (en) 2020-10-13
DK2662382T3 (en) 2016-06-27
RU2627710C2 (ru) 2017-08-10
HK1191654A1 (zh) 2014-08-01
PL2847204T3 (pl) 2018-06-29
ME02436B (me) 2016-09-20
JP6270823B2 (ja) 2018-01-31
RS54926B1 (sr) 2016-10-31
EP2847204A1 (en) 2015-03-18
BR112014026948B1 (pt) 2022-05-24
SI2847204T1 (en) 2018-05-31
CN104302655B (zh) 2018-04-03
RS57065B1 (sr) 2018-06-29
SI2662382T1 (sl) 2016-08-31
IN2014DN09437A (,) 2015-07-17
WO2013168096A1 (en) 2013-11-14
KR102160316B1 (ko) 2020-09-25
HRP20180345T1 (hr) 2018-06-01
EP2847204B1 (en) 2017-12-13
HUE037004T2 (hu) 2018-08-28
PT2662382T (pt) 2016-07-13
HK1207385A1 (en) 2016-01-29
CA2871714A1 (en) 2013-11-14
CY1120395T1 (el) 2019-07-10
RU2014149705A (ru) 2016-07-10
ES2580331T3 (es) 2016-08-23
EP2662382A1 (fr) 2013-11-13
CY1117723T1 (el) 2017-05-17
HRP20160624T1 (hr) 2016-08-12
BR112014026948A2 (pt) 2017-06-27
SMT201800147T1 (it) 2018-05-02
LT2847204T (lt) 2018-03-26
DK2847204T3 (en) 2018-03-12
KR20150013254A (ko) 2015-02-04
EP2662382B1 (fr) 2016-04-06

Similar Documents

Publication Publication Date Title
Tsepaeva et al. Design, synthesis, and cancer cell growth inhibitory activity of triphenylphosphonium derivatives of the triterpenoid betulin
CA2871714C (en) Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies
US7645748B2 (en) Sterol/stanol phosphorylnitroderivatives and use thereof
AU2015252859B2 (en) Bone-selective osteogenic oxysterol bisphosphonate analogs
EP2688902B1 (fr) Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
Białek-Pietras et al. Towards new boron carriers for boron neutron capture therapy: Metallacarboranes bearing cobalt, iron and chromium and their cholesterol conjugates
WO2007112572A1 (en) Sterols/stanols chemically linked to nitrogen releasing compounds and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
Sun et al. A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates
CN110357845B (zh) 一种淫羊藿苷元衍生物及其制备方法和用途
HK1207385B (en) Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies
CN118878600A (zh) 一种克服阿霉素耐药的脂质体前药的制备和应用
WO2023172132A1 (en) Dhcr24 inhibitory compounds
CN110357844B (zh) 一种淫羊藿苷元衍生物及其制备方法和用途
RU2440998C1 (ru) Производные 4-арилкумаринов и противоопухолевое лекарственное средство на их основе
Feng et al. Discovery of novel peptide–dehydroepiandrosterone hybrids inducing endoplasmic reticulum stress with effective in vitro and in vivo anti-melanoma activities
HK1191654B (en) Sterol derivatives, method for preparing same, pharmaceutical compositions containing same and use thereof for the treatment of multiple glioblastomas

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180427

EEER Examination request

Effective date: 20180427

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502